Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...
Kp-104 (vensobafusp alfa) advances as a Phase II/III-ready bifunctional complement biologic targeting alternative and terminal pathways, with rare renal Phase II basket interim reads in Q4 2026 and Q2 ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Consideration includes $6.75/share upfront cash and up to $2.50/share CVRs, implying ~$3.8B total value and ~40% premium to the 30‑day VWAP. BPL‑003 (intranasal mebufotenin benzoate/5‑MeO‑DMT) targets ...
Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
A two-track structure combines AI-native target discovery and generative chemistry with formulation, CMC, regulatory strategy, tech transfer, scale-up, and commercial supply to shorten the molecule-to ...
Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...
In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI ...
The collaboration is positioned as a translational bridge for researchers and entrepreneurs, offering an end-to-end discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results